|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0185117,
umls-concept:C0205210,
umls-concept:C0278701,
umls-concept:C1274040,
umls-concept:C1506928,
umls-concept:C1522673,
umls-concept:C1559154,
umls-concept:C1705438,
umls-concept:C2911684
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-1-3
|
|
pubmed:abstractText |
There are no reliable prognostic markers that identify gastric cancer patients who may benefit from adjuvant chemoradiation therapy. E2F-1 was shown to be associated with radiosensitivity and chemosensitivity in certain tumor types. Therefore, we analyzed expression and prognostic significance of E2F-1 along with thymidylate synthase (TS) in R(0)-resected gastric adenocarcinoma patients, who underwent adjuvant chemoradiation therapy with 5-fluorouracil (5-FU) and leucovorin.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:HeoJin SeokJS,
pubmed-author:KangWon KiWK,
pubmed-author:KimKyoung-MeeKM,
pubmed-author:KimSungS,
pubmed-author:LeeInkyoungI,
pubmed-author:LeeJeeyunJ,
pubmed-author:LimDo Hoondo H,
pubmed-author:LimHo YeongHY,
pubmed-author:LimTaekyuT,
pubmed-author:NohJae HyungJH,
pubmed-author:ParkCheol KeunCK,
pubmed-author:ParkJoon OhJO,
pubmed-author:ParkYoung SukYS,
pubmed-author:SohnTae SungTS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
82-8
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18172256-Adenocarcinoma,
pubmed-meshheading:18172256-Adult,
pubmed-meshheading:18172256-Aged,
pubmed-meshheading:18172256-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18172256-Blotting, Western,
pubmed-meshheading:18172256-Chemotherapy, Adjuvant,
pubmed-meshheading:18172256-Combined Modality Therapy,
pubmed-meshheading:18172256-Digestive System Surgical Procedures,
pubmed-meshheading:18172256-Disease-Free Survival,
pubmed-meshheading:18172256-E2F1 Transcription Factor,
pubmed-meshheading:18172256-Female,
pubmed-meshheading:18172256-Fluorouracil,
pubmed-meshheading:18172256-Humans,
pubmed-meshheading:18172256-Immunohistochemistry,
pubmed-meshheading:18172256-Kaplan-Meier Estimate,
pubmed-meshheading:18172256-Leucovorin,
pubmed-meshheading:18172256-Male,
pubmed-meshheading:18172256-Middle Aged,
pubmed-meshheading:18172256-Prognosis,
pubmed-meshheading:18172256-Radiotherapy, Adjuvant,
pubmed-meshheading:18172256-Stomach Neoplasms,
pubmed-meshheading:18172256-Survival Analysis,
pubmed-meshheading:18172256-Thymidylate Synthase,
pubmed-meshheading:18172256-Tissue Array Analysis,
pubmed-meshheading:18172256-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy.
|
|
pubmed:affiliation |
Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
